BNP Paribas Financial Markets’s Cellebrite CLBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$104K Sell
7,142
-106,977
-94% -$1.41M ﹤0.01% 4521
2026
Q1
$1.57M Buy
114,119
+109,206
+2,223% +$1.65M ﹤0.01% 2818
2025
Q4
$88.6K Buy
4,913
+169
+4% +$3.04K ﹤0.01% 4432
2025
Q3
$87.9K Sell
4,744
-381,650
-99% -$6M ﹤0.01% 4354
2025
Q2
$6.18M Sell
386,394
-17,848
-4% -$318K ﹤0.01% 1740
2025
Q1
$7.85M Buy
404,242
+62,090
+18% +$1.31M ﹤0.01% 1543
2024
Q4
$7.54M Buy
+342,152
New +$6.59M ﹤0.01% 1533

Other funds holding CLBT

BNP Paribas Financial Markets's CLBT Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Cellebrite (CLBT) stake by 94% in Q2 2026, selling an estimated $1.41M and leaving 7,142 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #4521.

BNP Paribas Financial Markets first reported a position in CLBT in Q4 2024 and has held it in 7 quarters since. The position peaked at $7.85M in Q1 2025. 186 funds tracked by Wall St. Rank hold CLBT as of Q2 2026.

  • BNP Paribas Financial Markets held 7,142 shares of Cellebrite worth $104K as of Q2 2026.
  • BNP Paribas Financial Markets sold 106,977 Cellebrite shares in Q2 2026, an estimated $1.41M.
  • Cellebrite made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4521 holding.
  • BNP Paribas Financial Markets first reported a position in Cellebrite in Q4 2024 and has held it in 7 quarters since.
  • BNP Paribas Financial Markets's Cellebrite position peaked at $7.85M in Q1 2025.
  • 186 funds tracked by Wall St. Rank held Cellebrite as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.